310 related articles for article (PubMed ID: 33789592)
1. Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Witte KK; Tsivgoulis G; Reynolds MR; Tsintzos SI; Eggington S; Ismyrloglou E; Lyon J; Huynh M; Egea M; de Brouwer B; Ziegler PD; Franco N; Joglekar R; Rosemas SC; Liu S; Thijs V
BMC Cardiovasc Disord; 2021 Mar; 21(1):160. PubMed ID: 33789592
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Diener HC; Chutinet A; Easton JD; Granger CB; Kleine E; Marquardt L; Meyerhoff J; Zini A; Sacco RL
Stroke; 2021 Mar; 52(3):1065-1068. PubMed ID: 33504190
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
Bahit MC; Sacco RL; Easton JD; Meyerhoff J; Cronin L; Kleine E; Grauer C; Brueckmann M; Diener HC; Lopes RD; Brainin M; Lyrer P; Wachter R; Segura T; Granger CB;
Circulation; 2021 Nov; 144(22):1738-1746. PubMed ID: 34649459
[TBL] [Abstract][Full Text] [Related]
4. Reexamination of the Embolic Stroke of Undetermined Source Concept.
Albers GW; Bernstein R; Brachmann J; Camm AJ; Fromm P; Goto S; Granger CB; Hohnloser SH; Hylek E; Krieger D; Passman R; Pines JM; Kowey P
Stroke; 2021 Aug; 52(8):2715-2722. PubMed ID: 34192898
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
[TBL] [Abstract][Full Text] [Related]
8. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
9. Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Ntaios G; Pearce LA; Veltkamp R; Sharma M; Kasner SE; Korompoki E; Milionis H; Mundl H; Berkowitz SD; Connolly SJ; Hart RG;
Stroke; 2020 Jun; 51(6):1797-1804. PubMed ID: 32295509
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation and Risk of Stroke Recurrence in Patients with Embolic Stroke of Undetermined Source Having No Potential Source of Embolism.
Sato N; Matsuo R; Kiyuna F; Nakamura K; Hata J; Wakisaka Y; Ago T; Kamouchi M; Kitazono T;
Cerebrovasc Dis; 2020; 49(6):601-608. PubMed ID: 33176316
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
13. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
Wells PS; Prins MH; Beyer-Westendorf J; Lensing AWA; Haskell L; Levitan B; Laliberté F; Ashton V; Xiao Y; Lejeune D; Crivera C; Lefebvre P; Zhao Q; Yuan Z; Schein J; Prandoni P
Chest; 2018 Dec; 154(6):1371-1378. PubMed ID: 30201406
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
Veltkamp R; Pearce LA; Korompoki E; Sharma M; Kasner SE; Toni D; Ameriso SF; Mundl H; Tatlisumak T; Hankey GJ; Lindgren A; Berkowitz SD; Arauz A; Ozturk S; Muir KW; Chamorro Á; Perera K; Shuaib A; Rudilosso S; Shoamanesh A; Connolly SJ; Hart RG
JAMA Neurol; 2020 Oct; 77(10):1233-1240. PubMed ID: 32628266
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
Hart RG; Veltkamp RC; Sheridan P; Sharma M; Kasner SE; Bangdiwala SI; Ntaios G; Shoamanesh A; Ameriso SF; Toni D; Czlonkowska A; Lindgren A; Hankey GJ; Perera KS; Shuaib A; Coutts SB; Gagliardi RJ; Berkowitz SD; Mundl H; Peters G; Connolly SJ;
J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2273-2279. PubMed ID: 31160218
[TBL] [Abstract][Full Text] [Related]
17. Atrial Fibrillation in Patients with Embolic Stroke of Undetermined Source during 3 Years of Prolonged Monitoring with an Implantable Loop Recorder.
Kitsiou A; Rogalewski A; Kalyani M; Deelawar S; Tribunyan S; Greeve I; Minnerup J; Israel C; Schäbitz WR
Thromb Haemost; 2021 Jun; 121(6):826-833. PubMed ID: 33401327
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Diener HC; Sacco RL; Easton JD; Granger CB; Bernstein RA; Uchiyama S; Kreuzer J; Cronin L; Cotton D; Grauer C; Brueckmann M; Chernyatina M; Donnan G; Ferro JM; Grond M; Kallmünzer B; Krupinski J; Lee BC; Lemmens R; Masjuan J; Odinak M; Saver JL; Schellinger PD; Toni D; Toyoda K;
N Engl J Med; 2019 May; 380(20):1906-1917. PubMed ID: 31091372
[TBL] [Abstract][Full Text] [Related]
19. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
20. Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
Noseworthy PA; Yao X; Gersh BJ; Hargraves I; Shah ND; Montori VM
Int J Cardiol; 2017 Oct; 245():174-177. PubMed ID: 28733071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
